ubiquinone and 3-nitrotyrosine

The purpose of this study was to determine the oxidative states of head and neck squamous cell carcinoma (HNSCC) patients by measuring their plasma levels of malondialdehyde (MDA), an indicator of lipid peroxidation, 3-nitrotyrosine (3-NT), an indicator of protein oxidation, and the coenzyme Q10 (CoQ10), an important antioxidant, and compare them with healthy individuals.. The plasma MDA, 3-NT and CoQ10 levels of 35 patients and 20 healthy individuals were measured with the high-performance liquid chromatography (HPLC) method. By comparing the patients' smoking habits, stage of the disease, size of the primary tumor and the presence of lymph nodes and the values of healthy individuals, the oxidative stress load of HNSCC patients was determined.. The mean plasma MDA levels of carcinoma patients were two times higher than those of healthy individuals (p < 0.001). When the mean plasma 3-NT levels of patients and healthy individuals were compared, no significant difference was found (p > 0.05). The mean plasma CoQ10 level of patients was low when compared with healthy individuals; however, no significant difference was detected (p > 0.05). In addition, as the stage and tumor size increased in HNSCC patients, their non-enzymatic antioxidant levels significantly decreased (p < 0.05).. In HNSCC patients, lipo-oxidative damage increased while nitrosative stress did not change; however, antioxidant activity decreased which in turn increased both lipid peroxidation and oxidative stress. These findings support the contention that oxidative stress strongly reflects the health status of HNSCC patients.

Topics: Adult; Aged; Aged, 80 and over; Antioxidants; Case-Control Studies; Chromatography, High Pressure Liquid; Female; Head and Neck Neoplasms; Humans; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Squamous Cell Carcinoma of Head and Neck; Tyrosine; Ubiquinone

Farnesol is a key metabolite of the mevalonate pathway and known as an antioxidant. We examined whether farnesol treatment protects the ischemic heart.. Male Wistar rats were treated orally with 0.2, 1, 5, and 50 mg/kg/day farnesol/vehicle for 12 days, respectively. On day 13, the effect of farnesol treatment on cardiac ischemic tolerance and biochemical changes was tested. Therefore, hearts were isolated and subjected either to 30 min coronary occlusion followed by 120 min reperfusion to measure infarct size or to 10 min aerobic perfusion to measure cardiac mevalonate pathway end-products (protein prenylation, cholesterol, coenzyme Q9, coenzyme Q10, dolichol), and 3-nitrotyrosine (oxidative/nitrosative stress marker), respectively. The cytoprotective effect of farnesol was also tested in cardiomyocytes subjected to simulated ischemia/reperfusion.. Farnesol pretreatment decreased infarct size in a U-shaped dose-response manner where 1 mg/kg/day dose reached a statistically significant reduction (22.3±3.9% vs. 40.9±6.1% of the area at risk, p<0.05). Farnesol showed a similar cytoprotection in cardiomyocytes. The cardioprotective dose of farnesol (1 mg/kg/day) significantly increased the marker of protein geranylgeranylation, but did not influence protein farnesylation, cardiac tissue cholesterol, coenzyme Q9, coenzyme Q10, and dolichol. While the cardioprotective dose of farnesol did not influence 3-nitrotyrosine, the highest dose of farnesol (50 mg/kg/day) tested did not show cardioprotection, however, it significantly decreased cardiac 3-nitrotyrosine.. This is the first demonstration that oral farnesol treatment reduces infarct size. The cardioprotective effect of farnesol likely involves increased protein geranylgeranylation and seems to be independent of the antioxidant effect of farnesol.

Topics: Animals; Animals, Newborn; Cardiotonic Agents; Cell Survival; Cells, Cultured; Cholesterol; Dolichols; Farnesol; Male; Mevalonic Acid; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Protein Prenylation; Rats; Rats, Wistar; Tyrosine; Ubiquinone

Vitamin A supplementation among women is a common habit worldwide in an attempt to slow aging progression due to the antioxidant potential attributed to retinoids. Nonetheless, vitamin A elicits a myriad of side effects that result from either therapeutic or inadvertent intake at varying doses for different periods. The mechanism behind such effects remains to be elucidated. In this regard, we performed the present work aiming to investigate the effects of vitamin A supplementation at 100, 200, or 500IU/kgday(-1) for 2 months on female rat brain, analyzing tissue lipid peroxidation levels, antioxidant enzyme activities (both Cu/Zn-superoxide dismutase - SOD - and Mn-SOD); glutathione S-transferase (GST) and monoamine oxidase (MAO) enzyme activity; mitochondrial respiratory chain activity and redox parameters in mitochondrial membranes, as well as quantifying α- and β-synucleins, β-amyloid peptide(1-40), immunoglobulin heavy-chain binding protein/78kDa glucose-regulated protein (BiP/GRP78), receptor for advanced glycation end products (RAGE), D2 receptor, and tumor necrosis factor-α (TNF-α) contents in rat frontal cortex, hippocampus, striatum, and cerebellum. We observed increased lipid peroxidation marker levels, altered Cu/Zn-SOD and Mn-SOD enzyme activities, mitochondrial nitrosative stress, and impaired respiratory chain activity in such brain regions. On the other hand, we did not find any change in MAO and GST enzyme activities, and on α- and β-synucleins, β-amyloid peptide(1-40), GRP78/BiP, RAGE, D2 receptor, and TNF-α contents. Importantly, we did not observed any evidence regarding an antioxidant effect of such vitamin at low doses in this experimental model. The use of vitamin A as an antioxidant therapy among women needs to be reexamined.

Topics: Amyloid beta-Peptides; Animals; Antioxidants; Brain Chemistry; Electron Transport; Enzyme-Linked Immunosorbent Assay; Estrous Cycle; Female; Glycation End Products, Advanced; Mitochondrial Diseases; Mitochondrial Membranes; Monoamine Oxidase; Oxidative Stress; Rats; Rats, Wistar; Receptors, Dopamine D2; Succinate Dehydrogenase; Superoxide Dismutase; Synucleins; Thiobarbituric Acid Reactive Substances; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquinone; Vitamin A; Vitamins

Considerable evidence suggests that mitochondrial dysfunction and oxidative stress contribute to the progression of Alzheimer's disease (AD). We examined the ability of the novel mitochondria-targeted antioxidant MitoQ (mitoquinone mesylate: [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cycloheexadienl-yl) decyl triphenylphosphonium methanesulfonate]) to prevent AD-like pathology in mouse cortical neurons in cell culture and in a triple transgenic mouse model of AD (3xTg-AD). MitoQ attenuated β-amyloid (Aβ)-induced neurotoxicity in cortical neurons and also prevented increased production of reactive species and loss of mitochondrial membrane potential (Δψ(m)) in them. To determine whether the mitochondrial protection conferred by MitoQ was sufficient to prevent the emergence of AD-like neuropathology in vivo, we treated young female 3xTg-AD mice with MitoQ for 5 months and analyzed the effect on the progression of AD-like pathologies. Our results show that MitoQ prevented cognitive decline in these mice as well as oxidative stress, Aβ accumulation, astrogliosis, synaptic loss, and caspase activation in their brains. The work presented herein suggests a central role for mitochondria in neurodegeneration and provides evidence supporting the use of mitochondria-targeted therapeutics in diseases involving oxidative stress and metabolic failure, namely AD.

Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Animals, Newborn; Antioxidants; Caspases; Cell Death; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Glial Fibrillary Acidic Protein; Gliosis; Glutathione; Humans; Lipid Peroxidation; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mitochondria; Neurons; Organophosphorus Compounds; Oxidative Stress; Peptide Fragments; Retention, Psychology; Rhodamines; Space Perception; Time Factors; Tyrosine; Ubiquinone

Metabolic syndrome (MetS) is a group of cardiovascular risk factors, including visceral obesity, glucose intolerance, hypertension, and dyslipidemia. Increased oxidative and nitrative stress and inflammation and decreased endothelial function occur in an animal model of metabolic syndrome, SHR/NDmcr-cp (SHR/cp) rats. The present study investigated the effects of coenzyme Q10 (CoQ10), one of the important antioxidants, on the abnormal oxidative condition and characteristic components of metabolic syndrome in SHR/cp rats by maintaining them on a diet supplemented with 0.07% - 0.7% CoQ10 for 26 weeks. We determined serum levels of oxidatively modified low-density lipoprotein (Ox-LDL) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) as oxidative stress markers, 3-nitrotyrosine as a nitrative stress marker, 3-chlorotyrosine as a marker of myeloperoxidase (MPO)-catalyzed oxidation and high-sensitivity C-reactive protein (hsCRP) as an inflammatory marker. The administration of CoQ10 significantly attenuated the increase of oxidative and nitrative stress markers and inflammatory markers in a dose-dependent manner. CoQ10 prevented the elevated serum insulin levels, although it did not affect the elevated glucose level and dyslipidemia. CoQ10 also reduced elevated blood pressure, but did not affect body weight gain. In addition, CoQ10 improved endothelial dysfunction in the mesenteric arteries. These findings suggest that the antioxidant properties of CoQ10 can be effective for ameliorating cardiovascular risk in MetS.

Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Blood Glucose; Body Weight; Deoxyguanosine; Disease Models, Animal; Inflammation; Insulin; Lipids; Lipoproteins, LDL; Metabolic Syndrome; Oxidative Stress; Peroxidase; Rats; Rats, Inbred SHR; Tyrosine; Ubiquinone

Inflamed tissues generate reactive nitrogen oxide species (RNO(x)), such as peroxynitrite (ONOO-)and nitryl chloride (NO2Cl), which lead to formation of nitrated DNA and protein adducts, including 8-nitroguanine (8NG), 8-nitroxanthine (8NX), and 3-nitrotyrosine (3NT). Once formed, the two nitrated DNA adducts are not stable in DNA and undergo spontaneous depurination. Nitration of protein tyrosine leads to inactivation of protein functions and 3NT has been detected in various disease states. We herein report that reduction of these nitro adducts to their corresponding amino analogues can be catalyzed by lipoyl dehydrogenases (EC 1.8.1.4) from Clostridium kluyveri (ck) and from porcine heart (ph) using NAD(P)H as the cofactor. We also found that dihydrolipoic acid (DHLA) and ubiquinol can be used as effective cofactors for reduction of 8NG, 8NX, and 3NT by these lipoyl dehydrogenases. The reduction efficiency of the mammalian enzyme is higher than the bacterial isozyme. The preference of cofactors by both lipoyl dehydrogenases is DHLA>NAD(P)H>ubiquinol. In all the systems examined, the nitrated purines are reduced to a greater extent than 3NT under the same conditions. We also demonstrate that this lipoyl dehydrogenase/antioxidant system is effective in reducing nitrated purine on NO2Cl-treated double stranded calf thymus DNA, and thus decreases apurinic site formation. The nitroreductase activity for lipoyl dehydrogenase might represent a possible metabolic pathway to reverse the process of biological nitration.

Topics: Dihydrolipoamide Dehydrogenase; Guanine; NADP; Nitrogen Oxides; Oxidation-Reduction; Reactive Nitrogen Species; Thioctic Acid; Tyrosine; Ubiquinone; Xanthines